Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar

Abstract Introduction The high cost of trastuzumab (Herceptin®) limits its accessibility for patients worldwide. Biosimilars, such as Tuznue® (HD201), represent a promising alternative to improve access to this essential therapy for HER2-positive breast cancer. This study aims to assess the similari...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Herve Bischoff, Neil K. O’Connor, Jamie Kim, Bogdan V. Popescu, Cecile Bigot, Sumita Pradhan, Rusha Chakraborty, Litha Jaison, Fathima Majeed, Lisa S. Park, Lotfi Boudali, Alexandre Detappe, Xavier Pivot, Pierre Coliat
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Adis, Springer Healthcare 2025-04-01
Sarja:	Drugs in R&D
Linkit:	https://doi.org/10.1007/s40268-025-00505-w
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!